Sigilon Therapeutics, Inc.
SGTX · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 21.4% | 83.7% | -37.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -116.7% | -132.8% | -164.1% | -182.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -127.2% | -154.6% | -213.3% | -209.8% |
| EPS Diluted | -0.23 | -0.23 | -0.17 | -0.28 |
| % Growth | 0% | -35.3% | 39.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |